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Abstract
At present, colistin is among the few antibiotics effective against Acinetobacter baumannii clinical isolates. However, in the last few years,
colistin-resistant A. baumannii strains have been isolated. Therefore, antibiotics effective against these usually pan-resistant colistin-
resistant A. baumannii strains are required. The main objective of this study was to analyse the activity of 15 peptides against colistin-
susceptible and colistin-resistant A. baumannii. The MICs were determined by microdilution. Among these 15 antimicrobial peptides
(AMPs), melittin, indolicidin and mastoparan showed good activity against both colistin-susceptible and colistin-resistant A. baumannii.
Further studies of mastoparan with time-killing curves showed bactericidal activity at MIC ·8 for both colistin-susceptible and colistin-
resistant A. baumannii. In conclusion, mastoparan may be a potential alternative for the treatment of colistin-resistant A. baumannii infections.
Keywords: Acinetobacter baumannii, antimicrobial peptides, colistin, multiresistance, susceptibility, time-killing curves
Original Submission: 26 February 2011; Revised Submission: 2 May 2011; Accepted: 6 May 2011
Editor: D. Raoult
Article published online: 18 May 2011
Clin Microbiol Infect 2012; 18: 383–387
10.1111/j.1469-0691.2011.03581.x
Corresponding author: J. Vila, Department of Clinical Microbiology,
Hospital Clinic, Villaroel 170, 08036, Barcelona, Spain
E-mail: jvila@ub.edu
Introduction
Acinetobacter baumannii is a Gram-negative, non-fermentative,
catalase-positive and oxidase-negative bacillus [1]. In the last
30 years, A. baumannii has evolved from being an underesti-
mated microorganism to one of the most important agents
causing nosocomial infections, mainly in immunocompro-
mised patients [2]. One of the main features of A. baumannii
is resistance to multiple antimicrobial agents, which can
impair the treatment of infections caused by multidrug-resis-
tant strains [3–5]. Different factors contribute to this multi-
resistance: (i) the acquisition of genetic elements such as
plasmids, resistant islands, transposons and integrons; (ii) the
ability to live on dry surfaces for long periods of time; and
(iii) the intrinsic resistance that this microorganism presents
[2,6–8].
Multiresistance has been associated with the acquisition of
resistance islands, which can carry resistance genes. For
instance, up to 52 resistance genes have been identified in
the resistance island described in the A. baumannii AYE strain
[9]. However, multiresistance can also be related to the indi-
vidual contributions of different mechanisms of resistance.
Carbapenems were the last active antibiotics used in the
treatment of A. baumannii strains [10–12]. Nowadays, the
increased resistance to carbapenems has led to the intensive
use of colistin (polymixin E) as a therapeutic alternative.
However, colistin-resistant A. baumannii clinical isolates have
already been described [13–15]. The mechanism of this colis-
tin resistance is not clear, but it seems to be related to the
loss or structural change of the lipopolysaccharide associated
with mutations in the lpx and pmrAB genes, respectively [16–
18]. Given the increased use of colistin, the number of colis-
tin-resistant A. baumannii strains will probably increase.
Therefore, it is important to find new antimicrobial agents
that are active against pan-resistant A. baumannii. Two
approaches can be used to find new antibacterial agents.
The first is to improve an existing antimicrobial agent by
changing its structure and thereby increasing its activity or
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circumventing the mechanism of resistance, and the second
is to find a completely new antimicrobial agent with a new
protein or molecular target [19]. The objective of this study
was to investigate the activity of 15 peptides against colistin-
susceptible and colistin-resistant A. baumannii.
Materials and Methods
Bacterial strains
Wild-type A. baumannii ATCC 19606 and a colistin-resistant
A. baumannii ATCC 19606 mutant were used in this study.
Colistin-resistant A. baumannii ATCC 19606 is a mutant gen-
erated with a multi-stepwise method. These strains were
used for the first screening of the selected peptides. We also
used 14 colistin-susceptible A. baumannii clinical isolates
belonging to different clones, to determine the activity of the
peptides, and to calculate MIC50 and MIC90, and 13 colistin-
resistant A. baumannii clinical isolates to calculate MIC50 and
MIC90; these 13 pan-resistant strains were isolated in a
hospital outbreak [20] and derived from the same clone
(REP-PCR). They presented similar antibiotic susceptibility
patterns, being resistant to sulbactam, piperacillin–tazobactam,
aztreonam, ceftriaxone, ceftazidime, cefotaxime, cefepime,
imipenem, meropenem, ciprofloxacin, ofloxacin, co-trimoxa-
zole, tetracycline, minocycline, gentamicin, tobramycin, amika-
cin and colistin. However, these strains were selected
because of their different colistin MIC values (broth micro-
dilution), ranging from 32 to >512 mg/L.
Susceptibility testing
The MICs of all peptides used in this study were deter-
mined against A. baumannii strains with the microdilution
method, following the CLSI recommendations [21]. The
concentrations of the peptides mastoparan, indolicidin,
colistin sulphate, histatin 5, cecropin B, cecropin A, magai-
nin II, buforin I, magainin I, histatin 8, bactenicin and melit-
tin ranged from 256 to 0.5 mg/L. The concentrations of
HNP-1 and HNP-2 ranged from 50 to 0.09 mg/L, and
those for cecropin P1 and b-defensin ranged from 25 to
0.05 mg/L.
Peptides
The peptides used in this experiment (Table 1) were
obtained from Sigma-Aldrich (St Louis, MO, USA), except for
buforin I (Anaspec, San Jose, CA, USA) and bactenicin (Gen-
script, Piscataway, NJ, USA). The peptides were dissolved in
water, and the concentration used for the MICs was
1024 mg/L, except for HNP-1, HNP-2 (200 mg/L), cecr-
opin P1 and b-defensin (102.4 mg/L). All peptide solutions
were stored at )20ºC.
Time-killing curves
Time-killing curves were obtained with mastoparan, the
peptide presenting the best activity against colistin-suscepti-
ble and colistin-resistant A. baumannii ATCC strains. Initial
inocula between 1 · 106 and 5 · 106 CFU/mL of A. bau-
mannii in 10-mL aliquots of Mueller–Hinton broth were
prepared for the time-killing curves. Concentrations of
MIC ·1-fold, MIC ·2, MIC ·4 and MIC ·8 were used for
mastoparan. Samples were taken at 0, 4, 7 and 24 h after
incubation. Drug carryover was addressed by dilution. An
antibiotic is considered to be bactericidal when a reduc-
tion of 3 log10 CFU/mL as compared with the initial inocu-
lum is achieved [22]. These experiments were performed
in duplicate.
TABLE 1. Peptides used in this study
Name Sequence Source Structure
Mastoparan INLKALAALAKKIL Vespula lewisii Helix
Indolicidin ILPWKWPWWPWRR Bovine neutrophils Rich
Colistin N-(4-amino-1-(1-(4-amino-1-oxo-1-(3,12,23-tris
(2-aminoethyl)-20-(1-hydroxyethyl)-6,9-diisobutyl-2,5,8,
11,14,19,22-heptaoxo-1,4,7,10,13,
18-hexaazacyclotricosan-15-ylamino)butan-2-ylamino)-3-
hydroxybutan-2-ylamino)-1-oxobutan-2-yl)-N5-
dimethylheptanamide
Bacillus polymyxa Cyclic peptide
Histatin 5 DSHAKRHHGYKRKFHEKHHSHRGY Homo sapiens Helix
Cecropin B KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL Chinese oak silk moth Unknown
Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Hyalophora cecropici Helix
Magainin II GIGKFLHSAKKFGKAFVGEIMNS African Helix
Cecropin P1 SWLSKTAKKLENSAKKRISEGIAIAIQGGPR Pig Helix
b-Defensin DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK Homo sapiens Bridge (three S–S)
Buforin I AGRGKQGGKVRAKAKTRSSRAGLQFPVGRVHRLLRKGNY Bufo bufo gargarizans Unknown
Magainin I GIGKFLHSAGKFGKAFVGEIMKS African clawed frog Xenopus laevis Unknown
HNP-1 ACYCRIPACIAGERRYGTCIYQGRLWAFCC Homo sapiens Bridge
HNP-2 CYCRIPACIAGERRYGTCIYQGRLWAFCC Homo sapiens Bridge
Histatin 8 KFHEKHHSHRGY Homo sapiens Fragment of histatin 5
Bactenicin RLCRIVVIRVCR Bovine neutrophils Bridge
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Honeybee venom Helix
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Results
In vitro activity of antimicrobial peptides (AMPs) against
colistin-susceptible and colistin-resistant A. baumannii
Fifteen different AMPs were tested against colistin-suscepti-
ble and colistin-resistant A. baumannii. The MICs are shown
in Table 2. Mastoparan and melittin showed the lowest MIC,
at 4 mg/L each for colistin-susceptible A. baumannii, and 1
and 2 mg/L for colistin-resistant A. baumannii, respectively.
Indolicidin showed MICs of 8 and 16 mg/L for colistin-
susceptible A. baumannii and colistin-resistant A. baumannii,
respectively. HNP-1 (3.25 mg/L) showed good activity against
colistin-resistant A. baumannii. However, the MIC for colistin-
susceptible A. baumannii was 50 mg/L. The other AMPs
showed higher MICs (>25 mg/L) for both colistin-susceptible
and colistin-resistant A. baumannii. The MIC50 and MIC90 of
mastoparan and indolicidin as compared with colistin were
determined for 14 colistin-susceptible A. baumannii clinical iso-
lates that were epidemiologically unrelated, and the results
are shown in Table 3. The results showed lower MICs for
mastoparan (MIC50 4 mg/L) than for indolicidin
(MIC50 16 mg/L), but their MICs were higher than colistin
for colistin-susceptible A. baumannii (MIC50 <0.5 mg/L).
Mastoparan and indolicidin were also tested against 13 colis-
tin-resistant A. baumannii clinical isolates, and the results are
also shown in Table 3. In this case, the results showed better
activity for mastoparan (MIC50 8 mg/L) than for colistin
(MIC50 >512 mg/L) and indolicidin (MIC50 16 mg/L).
Time-killing curves
Time-killing curves were obtained for mastoparan to investi-
gate the bactericidal activity of this peptide against colistin-
susceptible and colistin-resistant A. baumannii (Fig. 1). Mas-
toparan showed the same bactericidal activity for both colis-
tin-susceptible and colistin-resistant A. baumannii at the
highest concentration used (MIC ·8), being bactericidal along
the curve. Mastoparan at MIC ·4 showed bactericidal activity
against colistin-resistant A. baumannii, but not against colistin-
susceptible A. baumannii. For the rest of the mastoparan con-
centrations used, no bactericidal activity at any point along
the curve was observed, with activity increasing in the first
sample and then decreasing along the curve.
Discussion
Among the peptides investigated, cecropin P1, colistin, me-
littin, indolicidin and mastoparan showed activity against
TABLE 2. MICs (mg/L) of different peptides against colistin-
susceptible and colistin-resistant Acinetobacter baumannii
Antimicrobial
peptide
Colistin-susceptible
A. baumannii
(ATCC 19606-wt)
Colistin-resistant
A. baumannii
(ATCC 19606-mutant)
Bactenicin 64 16
Buforin I >256 >256
Cecropin A 32 256
Cecropin B 32 128
Cecropin P1 1.6 >25
Colistin 0.5 256
Histatin 5 >256 >256
Histatin 8 32 32
HNP-1 50 3.25
HNP-2 50 50
Indolicidin 8 16
Magainin I 64 64
Magainin II 256 256
Mastoparan 4 1
Melittin 4 2
b-Defensin 256 256
TABLE 3. MIC50 and MIC90 of different peptides for colistin-
susceptible and colistin-resistant Acinetobacter baumannii
clinical isolates (mg/L)
Strains
Antimicrobial
peptides MIC50 MIC90 Range
Colistin-susceptible
A. baumannii (14)
Mastoparan 4 8 1–16
Indolicidin 16 32 4–32
Colistin <0.5 <0.5 <0.5
Colistin-resistant
A. baumannii (13)
Mastoparan 8 8 2–8
Indolicidin 16 16 16
Colistin >512 >512 32 to >512
(a)
(b)
FIG. 1. Results of time-killing experiments. (a) Colistin-resistant
ATCC 19606 Acinetobacter baumannii incubated with mastoparan
(MIC 1 mg/L). (b) Colistin-susceptible ATCC 19606 A. baumannii
incubated with mastoparan (MIC 4 mg/L).
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colistin-susceptible A. baumannii, but only mastoparan and
melittin showed good activity against both colistin-suscepti-
ble and colistin-resistant A. baumannii. It is worthy of men-
tion that the HNP-1 showed good activity only against
colistin-resistant A. baumannii. In previous studies performed
by Saugar et al. [23] and Rodriguez-Hernandez et al. [24],
several hybrid peptides composed of a mixture of cecr-
opin A and melittin showed MICs of 2–8 mg/L against 13
clinical isolates of colistin-resistant (4–64 mg/L) A. baumannii.
In our study, the MICs were 4 mg/L for mastoparan against
colistin-susceptible A. baumannii and 1 mg/L for mastoparan
against colistin-resistant A. baumannii with an MIC for colis-
tin of 256 mg/L. On comparison of the MIC50 and MIC90 of
cecropin A–melittin and mastoparan for colistin-resistant
A. baumannii, they were found to be slightly lower, by one
or two dilutions, for cecropin A–melittin than for mastopa-
ran.
Several studies have investigated mastoparan activity, but
there has been no report on the activity of mastoparan
against A. baumannii [25]. In the study performed by Giaco-
metti et al. [26], a similar set of peptides was used, but only
against colistin-susceptible A. baumannii, with buforin II (MIC
range 0.25–16 mg/L), magainin II (MIC range 0.50–16 mg/L)
and cecropin A (MIC range 0.50–32 mg/L) being the most
active AMPs against colistin-susceptible A. baumannii, in con-
trast to our study, in which only cecropin P1 showed good
activity against colistin-susceptible A. baumannii. Mastoparan
is not the only peptide isolated from wasps. All of the pep-
tides isolated from wasps have very similar sequences, with
changes in only some amino acids, but their activity can vary,
changing from an MIC of 58 mg/L to one of 164 mg/L with
just one amino acid substitution in the peptide [27].
On comparison of the time-killing curves of mastoparan
and cecropin A–melittin, similar behaviour was seen. Cecropin
A–melittin was bactericidal at lower concentrations in some
strains tested, but in others there was regrowth that was
not observed in mastoparan time-killing curves [24].
In a study by Li et al. [14], a time-killing curve for colistin
against ATCC 19606 colistin-susceptible A. baumannii was
obtained. On comparison of this time-killing curve with that
obtained in our study with mastoparan, it can be seen that
the bactericidal effect of colistin was faster than that of
mastoparan. Moreover, colistin was bactericidal at lower
concentrations than mastoparan for colistin-susceptible
A. baumannii, but, in contrast, regrowth was observed in the
colistin time-killing curve that did not appear when mastopa-
ran was used.
The fact that mastoparan shows activity against both colis-
tin-susceptible and colistin-resistant A. baumannii may suggest
that the mechanisms of action used by mastoparan and colis-
tin are different. It is known that the mechanism of colistin is
related to disruption of the bacterial membrane [28]. Mas-
toparan could act as a cell-penetrating peptide, crossing the
bacterial membrane [29]. However, Li et al. [30] analysed
the effect of mastoparan against Escherichia coli and Staphylo-
coccus aureus by scanning electron microscopy, and suggested
that mastoparan acts on the cell surface, resulting in different
abnormalities depending on the microorganism. Future stud-
ies on the mechanism of action used by mastoparan, and also
on the in vivo activity of this AMP in an animal model of
pneumonia caused by A. baumannii, would be of interest. In
conclusion, mastoparan is a potential antimicrobial agent for
use against both colistin-susceptible and colistin-resistant
A. baumannii, and it may become, after further development,
a possible option when colistin-resistant A. baumannii strains
are found.
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